DMAC vs PHM · $157.4M cap vs P/E 7.7, rev $17.95B
DiaMedica Therapeutics Inc (DMAC) versus PulteGroup Inc (PHM) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
PulteGroup Inc (PHM) is a residential construction company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported PHM revenue for 2024-12-31 was $17.95B. Net income was $3.08B. Revenue was up 11.7% from 2023-12-31 to 2024-12-31. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
DMAC currently screens at market cap $157.4M. PHM currently screens at market cap $21.92B and trailing P/E 7.7.
Not investment advice. Open the DMAC and PHM stock pages for the full models.
Not investment advice.